Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.50 |
| ▸ | MDM4 | O15151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18406908 | 0.95 | MAPT (0.42) | MAPTLMNAMDM2MDM4ALDH1A1 | |
| SCHEMBL18406898 | 0.95 | MAPT (0.42) | MAPTLMNAMDM2MDM4ALDH1A1 | |
| SCHEMBL18405711 | 0.92 | MAPT (0.40) | MAPTLMNAMDM2MDM4ALDH1A1 | |
| SCHEMBL18405691 | 0.88 | HCAR2 (0.41) | MAPTLMNAMDM2MDM4ALDH1A1 | |
| SCHEMBL18405699 | 0.87 | MAPT (0.49) | MAPTLMNAMDM2MDM4ALDH1A1 | |
| SCHEMBL18405684 | 0.86 | MAPT (0.53) | MAPTLMNAMDM2MDM4ALDH1A1 | |
| SCHEMBL18405714 | 0.86 | MAPT (0.53) | MAPTLMNAMDM2MDM4ALDH1A1 | |
| SCHEMBL18405701 | 0.84 | MAPT (0.51) | MAPTLMNAMDM2MDM4ALDH1A1 | |
| SCHEMBL18405702 | 0.84 | MAPT (0.51) | MAPTLMNAMDM2MDM4ALDH1A1 | |
| SCHEMBL18406902 | 0.83 | MAPT (0.43) | MAPTLMNAMDM2MDM4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170020837-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170020837-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020837-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | MAPT 8/4885LMNA 4358/4885MDM2 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.